Compare Enveric Biosciences Inc (ENVB) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Wayfair Inc — how do they compare? Enveric Biosciences Inc trades at $1.4 (market cap $5.32M), while Wayfair Inc trades at $90.8 (market cap $12.10B). The key difference: Wayfair Inc is far larger — about 2274.4× Enveric Biosciences Inc's market cap, and Wayfair Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | W | |
|---|---|---|
Market Cap | $5.32M | $12.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $119.05 |
52-Week Low | $1.28 | $55.38 |
Enterprise Value | $408.82K | $14.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Wayfair (W) trades at $91.11, up 2.67% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue of $12.46B for 2025 but a net loss of $313M, though it has beaten earnings expectations in recent quarters. Positive sentiment is driven by analyst upgrades and news of expansion into brick-and-mortar stores and AI integration.
The outlook is cautiously optimistic given strong analyst buy ratings (51.78%) and a consensus price target of $93.58, slightly above current levels. Key risks include persistent net losses, high debt-to-asset ratio of 95.11%, and competitive e-commerce pressures. Earnings growth and cost management are critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
